Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-lipoic acid (ALA) is an endogenous antioxidant that has been studied for its potential anti-inflammatory properties, which has led to some scientific interest in its use for inflammatory conditions such as rheumatoid arthritis (RA). Several in vitro and animal studies have demonstrated that ALA can reduce markers of inflammation and oxidative stress, both of which are implicated in the pathogenesis of RA. Furthermore, ALA has been shown to inhibit the activation of nuclear factor-kappa B (NF-κB), a key regulator of inflammatory cytokine production relevant to RA.

A small number of human studies and clinical trials have evaluated the effects of ALA in patients with RA or related inflammatory arthritis. For example, a 2020 randomized controlled trial found that ALA supplementation, in combination with methotrexate, modestly improved oxidative stress markers and reduced some inflammatory parameters in RA patients. However, the number of trials is limited, sample sizes are small, and results are inconsistent regarding clinical outcomes such as pain and joint function.

In summary, while there is a scientific rationale for the use of ALA in RA based on its antioxidant and anti-inflammatory properties, and some preliminary human studies suggest possible benefits, the overall quality and quantity of evidence are insufficient to support its widespread use as an adjunct therapy for RA at this time.

More about Alpha-Lipoic Acid
More about Rheumatoid Arthritis

Other ingredients used for Rheumatoid Arthritis

Other health conditions supported by Alpha-Lipoic Acid

Products containing Alpha-Lipoic Acid